Two HAMA subdomain scores were calculated: (a) anxiety HAMA symptoms, which were defined as anxious mood + tension + fears + anxiety behavior during the interview
Binders are substances that can attract and attach to certain compounds in the gut
Zepbound Switching: How to Transition From or To Other GLP-1/GIP Drugs Safely At a glance Drug / Zepbound (tirzepatide), Eli Lilly Drug class / Dual GIP and GLP-1 receptor agonist Approved indication / Chronic weight management in adults with BMI 30, or 27 with one weight-related comorbidity Dosing frequency / Once weekly subcutaneous injection Starting dose / 2.5 mg weekly, escalated every 4 weeks Maximum dose / 15 mg weekly Key trial / SURMOUNT-1 (N=2,539): 20.9% mean body-weight loss at 72 weeks on 15 mg Half-life / Approximately 5 days (supports once-weekly dosing) Common switch scenarios / Semaglutide to tirzepatide, liraglutide to tirzepatide, tirzepatide to oral semaglutide FDA approval date / November 8, 2023 (weight management indication) How Zepbound Works: Mechanism at the Receptor Level Zepbound binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor
Additionally, tirzepatide actually mimics two hormones produced in the body in addition to being a GLP-1 agonist, it activates the glucose-dependent insulinotropic polypeptide hormone receptors
Duration: For visible results, use continuously for at least 812 weeks
Relieves DOMS, or delayed onset muscle soreness
